Join the Oncology Voice Network. Join for Free
How Information is Consumed
Medical Science Liaisons Andrew Fariello AstraZeneca data sharing technological advancements

How Information is Consumed


Share This Article


Summary

In this episode, Tom Caravela is joined by Andrew Fariello from AstraZeneca to explore the evolving landscape of Medical Science Liaisons (MSLs) in the context of data sharing and technological advancements. Andrew shares his career journey and insights into the growing importance of surveillance networks and real-world data, especially following the pandemic. The discussion delves into adapting MSL strategies to handle information overload while integrating patient perspectives into medical strategies. Andrew emphasizes the critical role of MSLs, highlighting advancements in engagement and innovative tools. The episode concludes with advice for MSLs navigating scientific developments and a call to action for listeners.

Today’s guest is Andrew Fariello, VP Global Medical Affairs, Head Medical Excellence, Oncology who discusses trends in information/data consumption and what MSLs can do for greater impact

We learn….

πŸ‘‰ How data is being shared as well as how it is being consumed
πŸ‘‰ What he means by the term “instantaneous Information”
πŸ‘‰ What role MSLs play in patient care and patient identification 
πŸ‘‰ How the MSL approach may need to change
πŸ‘‰ Areas of improvement for MSLs in KOL engagement

Click for Source
Medical Science Liaisons, Andrew Fariello, AstraZeneca, data sharing, technological advancements

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Podcast
Hiring Managers Beware: Reverse Rejection Explained!
Partner Avatar Michael Pietrack

Hiring Managers Beware: Reverse Rejection Explained!

Article
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies β€” and a Call to Candidates
OVN Avatar Jamie Riley

The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies β€” and a Call to Candidates

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Explore OVN